VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on July 17, 2026, regarding VolitionRx Limited, a Delaware corporation. The report details the results of the Company's 2026 Annual Meeting of Stockholders and the subsequent filing of a Certificate of Fourth Amendment to its Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Reduction of Authorized Shares: The Company filed an amendment to reduce its authorized common stock from 325,000,000 shares to 150,000,000 shares. This amendment became effective upon filing on July 17, 2026.
- Stockholder Meeting Attendance: On the record date of May 26, 2026, there were 8,627,191 shares outstanding. At the Annual Meeting, 4,261,161 shares were present in person or by proxy.
- Board Elections: Seven directors were elected to serve until the next annual meeting. All nominees received significant support, with "Votes For" ranging from approximately 2.08 million to 2.16 million.
- Accounting Firm Ratification: Stockholders ratified the selection of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm for the year ending December 31, 2026.
- Executive Compensation: A non-binding advisory vote on executive compensation was approved.
- Stock Incentive Plan: Stockholders approved the Company's 2026 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing does not provide management commentary on future financial guidance, operational outlook, or specific risk factors. The primary focus is on the successful execution of the Annual Meeting proposals and the legal amendment to the corporate charter.
Key Facts for Investor Verification
- Verify the impact of the authorized share reduction (from 325M to 150M) on future capital raising capabilities and potential stock splits.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Review the details of the approved 2026 Stock Incentive Plan to understand potential dilution from future equity grants.
- Check the definitive Proxy Statement (Schedule 14A filed June 2, 2026) for detailed descriptions of the proposals and executive compensation.